Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain

Last updated: November 12, 2024
Sponsor: RDC Clinical Pty Ltd
Overall Status: Completed

Phase

4

Condition

Dysmenorrhea (Painful Periods)

Female Hormonal Deficiencies/abnormalities

Premenstrual Syndrome

Treatment

Levagen+

Microcrystalline cellulose

Clinical Study ID

NCT05810116
PEAMPS-23
  • Ages > 18
  • Female

Study Summary

This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Palmitoylethanolamide (PEA) compared to placebo on menstrual pain in otherwise healthy participants 18 years and over.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Women who experience mild to moderate menstruating pain

  • Aged 18 years or over

  • History of over the counter (OTC) analgesic use for the treatment of menstrual pain

  • Self-reported history of menstrual cramp pain occurring during four of the past sixmenstrual cycles.

  • Typically requires at least one dose of an OTC analgesic medication such asnaproxen, aspirin, ibuprofen or acetaminophen taken on at least 1 day of menstrualcycle for the treatment of mild to moderate menstrual cramp, and normallyexperiences pain relief from these medications.

  • Otherwise healthy

  • Able to provide informed consent

  • Regular menstrual cycle (28 days ± 7 days) and period

  • Agree not to participate in any other clinical trial while enrolled in this trial

Exclusion

Exclusion Criteria:

  • Secondary cause for dysmenorrhea (i.e. endometriosis, adenomyosis, uterine fibroidsor infection)

  • Any bleeding disorders, recent surgery or concurrent blood thinning treatment

  • Unstable or serious illness (e.g., kidney, liver, GIT, heart conditions, diabetes,thyroid gland function, lung conditions, chronic asthma, diagnosed psychological ormood disorder) (1)

  • Current malignancy (excluding BCC) or chemotherapy or radiotherapy treatment formalignancy within the previous 2 years

  • Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or otheranticoagulation therapy

  • Pregnant or lactating women

  • Active smokers, nicotine use or drug (prescription or illegal substances) abuse

  • Chronic past and/or current alcohol use (>14 alcoholic drinks week)

  • Allergic or hypersensitive to any of the ingredients in active or placebo formula

  • Any condition which in the opinion of the investigator makes the participantunsuitable for inclusion

  • Participated in any other clinical trial during the past 1 month

  1. An unstable illness is any illness that is currently not being treated with astable dose of medication or is fluctuating in severity. A serious illness is acondition that carries a risk of mortality, negatively impacts quality of lifeand daily function and/or is burdensome in symptoms and/or treatments.

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Levagen+
Phase: 4
Study Start date:
May 19, 2023
Estimated Completion Date:
December 20, 2023

Connect with a study center

  • RDC Clinical Pty Ltd

    New Farm, Queensland 4006
    Australia

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.